Prevalence and prognostic significance of restriction versus systolic dysfunction in patients with transthyretin and light chain cardiac amyloidosis

30 August 2024 (08:45 - 08:55)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Mattia Zampieri

Meyer University Hospital, Florence (Italy)

4 More presentations in this session

Presentation thumbnail

Patient characteristics and incidence of cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records

Doctor L. Anderson (London, GB)

Abstract Slides Video

Presentation thumbnail

Usefulness of scintigraphy with [99mTc]Tc-DPD for the detection of transthyretin cardiac amyloidosis. Reference centre experience in an endemic area.

Doctor N. Orta (Palma de Mallorca, ES)

Abstract Slides Video

Presentation thumbnail

Cardiac magnetic resonance T1 imaging for the diagnosis of cardiac amyloidosis among patients with symptomatic heart failure

Doctor R. Gessner (Leipzig, DE)

Abstract Slides Video

Presentation thumbnail

Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis

Mr S. Muller (Utrecht, NL)

Abstract Slides Video

Access the full session

Session thumbnail

Cardiac amyloidosis: my heart is filled with so much…

The Event

Event poster

ESC Congress 2024

30 August 2024 08:45 CET

You may be interested in

Congress Presentation

Cardiac amyloidosis and heart failure phenotypes: a prognostic study of systolic function markers

Congress Presentation

Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction

Congress Presentation

Echocardiography as first-line technique in suspected cardiac amyloidosis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources